Wednesday, October 4, 2023
Wednesday, October 4, 2023

Contact: 561.316.3330

Telli Health Announces Verizon Certification, Becomes 1st Medical IoT Device Company to Operate on Their Cellular Network

Telli Health today announced that it has been certified by Verizon, allowing all of its devices to operate on Verizon, America’s largest and most reliable cellular network. With Verizon’s vast cellular footprint, patients can take a reading from anywhere and know it will be sent instantly to their provider. Telli Health’s connected care devices are the first and only Verizon-certified devices in the United States.

The remote patient monitoring (RPM) industry has long suffered from deficient reliability in transmitting patient readings, as well as the ability to take readings from anywhere. Being Verizon certified will improve this, and for healthcare providers and RPM companies, this means increased patient adherence—a primary goal for both.

Telli Health’s devices use SIM technology that connects to all major cellular carriers in the United States, including AT&T and T-Mobile/Sprint, in addition to Verizon. Globally, coverage includes over 650 cellular carriers in 191 countries.

Jeff Bartzen, Sales Executive at Telli Health, commented, “Our competitors typically use Bluetooth and antiquated third-party technology for their remote care medical devices. This presents problems ranging from connectivity issues to requiring cell phones and difficult pairing for an aging population. Our competitors are only now starting to use cellular-connected devices—which is easier and the way of the future—but they only work on either AT&T or T-Mobile. I am very pleased that we have partnered with Verizon to deliver value-based in-home healthcare to more people than ever before, securing Telli Health as the premier destination for reliable, accurate, accessible, and easy-to-use connected care medical devices. Physicians can trust 4G cellular technology as a tremendous improvement over current devices plagued by connectivity issues and unreliability.”

According to a Telli Health case study with one of the industry’s leading RPM providers, from 2018 through 2020, options for cellular-connection blood pressure and blood glucose devices were very limited despite demand. From high rates of data transmission failures to issues related to accuracy and ease of use, the devices in the marketplace were not up to industry standards. Telli Health entered in 2021, offering 4G cellular-enabled devices that directly addressed these specific issues. Telli Health blood pressure monitors and blood glucose meters consistently delivered accurate and reliable readings. The RPM company reported on average a 10 mmHg reduction in both systolic and diastolic blood pressures, with some patients seeing as much as 30 mmHg reductions. Also observed were increased patient satisfaction, a 50% reduction in patient churn due to accuracy, consistency, and reliability of data transmission using Telli Health devices, and an overall 30% improvement in daily compliance and successful transmissions in which providers received substantially more patient readings. Now being Verizon certified, Telli Health looks forward to expanding these successes with the world’s first touchless 4G Thermometer, 4G Weight Scale (December 2021), and the world’s first 4G Pulse Oximeter (December 2021).

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Centinel Spine’s prodisc ® Continues to Change Lives After Over 30 Years and 250,000 Total Disc Replacement Implantations

The prodisc lumbar and cervical technologies will be highlighted by Centinel Spine at the upcoming 2023 annual EUROSPINE meeting and congress in Frankfurt, Germany (October 4-6, 2023). The prodisc technology portfolio now includes four cervical and two lumbar devices—5 approved by the FDA—and has been validated with a reported reoperation rate of less than 1%.

Amber Implants Announces Start of Clinical Trial with VCFix® Spinal System

This first-in-human clinical trial will assess the safety and effectiveness of the VCFix® Spinal System implant for patients suffering from vertebral compression fractures. The implant is provided with a user-friendly, single-use sterile surgical kit, ensuring perfect traceability and reducing the risk of infection. 

RaySearch Deepens Collaboration with P-Cure

The expanded collaboration will enable users of the P-Cure proton therapy system to use RayStation and RayCare in a seamlessly integrated environment. The P-Cure system is a gantry-less seated proton system, designed to fit within linac vaults, that has recently been cleared by the FDA. It is used clinically by the Hadassah Medical Center in Jerusalem – the only proton facility in the Middle East – to treat CNS, head and neck, thoracic and pancreatic malignancies.

Edinburgh-based Med-tech Firm in MBO to Expand Into New Markets and Technologies

The acquisition will enable Novarum to build on its strong lateral flow test customer base and extend into adjacent markets. 

Biomic Sciences Issues Voluntary Nationwide Recall of ION* Sinus Support, ION* Biome Sinus, and Restore Sinus Spray Products Due to Microbial Contamination

Risk Statement: In the population most at risk, patients or individuals who recently underwent nasal or sinus surgery, there is a reasonable probability that the use of the affected product could potentially result in severe or life-threatening adverse events such as bacteremia or fungemia, invasive bacterial or fungal rhinosinusitis, or disseminated fungal infection. To date, Biomic Sciences has not received any reports of adverse events related to this product.

By using this website you agree to accept Medical Device News Magazine Privacy Policy